DUBAI, UAE, Oct. 27, 2021 /PRNewswire/ -- A global healthcare company with the vision of creating a better and healthier every day for every woman around the world, Organon hosted a thought leadership panel discussion, "Accelerating advancements in the health of women across the region" forum at EXPO 2020. Held in partnership with the United States Chamber of Commerce, the USA Pavilion, Jhpiego and Friends of Cancer Patients, Organon convened the forum of global experts and industry thought-leaders to better understand the existing gaps in women's healthcare and explore potential solutions. Attended by many distinguished guests, among them His Excellency Dr Amin Al Amiri and Megan Gregonis, the United States Consul General in Dubai the forum marked the launch of Organon in the MENAT region.
With a diverse portfolio spanning Women's Health, Biosimilars and Established Brands, Organon is the only company globally focusing exclusively on women's health. Keen to shift the focus of women's healthcare beyond female reproduction to unaddressed needs, the healthcare company, which serves 140 markets with 60 medicines and solutions, is now operating across UAE, Oman, Kuwait, Qatar, KSA, Egypt, Lebanon, Jordan, Turkey and Ukraine. In line with the UN Sustainable Development Goal for gender equality and female empowerment, Organon's mission is to improve and innovate across the women's healthcare space.
Commenting on the launch, Ramy Koussa, Associate Vice President, Organon MENAT, said, "Our goal is to advance women's healthcare across MENAT by addressing their unmet needs, helping to build a healthier and a brighter future for all women, families and communities. Leveraging our existing global footprint and expertise and working closely with local authorities and industry stakeholders, we are keen to shift the women's health paradigm beyond reproductive health to encompass the entire life cycle. This forum is an important first for us at Organon MENAT in providing a platform to listen to women and becoming a trusted women's healthcare partner in the region," he added.
Among the topics discussed by the distinguished women's healthcare experts were existing gaps in data that act as a barrier to improving women's health, how to monitor progress toward the UN Sustainable Goal of gender equality, investments in healthcare and accelerating change through economic empowerment. Attending panelists included: Dr Susanne Fiedler, Chief Commercial Officer of Organon; Susanne Mikhail, Regional Director of the United Nations Entity for Gender Equality and the Empowerment of Women for the Arab States; Bathylle Missika, Head of the Networks, Partnerships and Gender Division at OECD Development Centre; Myra Betron, Director of Gender at Jhpeigo; and Dina El- Shenoufy, Chief Investment Officer at Flat6lab.
Ms. Susanne Mikhail, Regional Director of the United Nations Entity for Gender Equality and the Empowerment of Women for the Arab States, said, "Better understanding and addressing women's unmet healthcare needs is essential to achieving the Sustainable Goals of the 2030 Agenda, including the critically important goals of gender equality and female economic empowerment. Besides looking at health services as a basic right by itself, women's health is directly related to economic development as well. For example, women could add $28 trillion (or 26% of global GDP) to the global economy by 2025, if their health issues are addressed, allowing them to participate in the labor market more fully. Therefore, it is exciting to see Organon focusing on the health needs of women and accelerating advancements in women's health in this region."
Commenting following the panel discussion, Dr Susanne Fiedler, Chief Commercial Officer, Organon, said, "At Organon, we are working toward a world where every woman enjoys better health. It is imperative that, as a company, we not only listen to but learn from women about what of their current needs are not being addressed. To that end, we will work closely together with industry stakeholders from private through to public organizations, healthcare providers, patient societies and others, establishing efficient and differentiated operating models to improve the delivery of women's healthcare services across the region."
Dr Sawsan A. S. Al Madhi, Director General, Friends of Cancer Patients, added, "Friends of Cancer Patients (FOCP) is a patient-centric organization. We fundamentally believe that to provide the best care possible, the patient must be heard and empowered. We welcome the launch of Organon across the Middle East, North Africa and Turkey region, and look forward to our collaborative approach to better understanding and addressing the unmet health needs of women."
With a dynamic business model and entrepreneurial approach and in line with their commitment to accelerate advancements in women's health, the company has also announced the launch of the Femtech Accelerator Program in the Middle East and North Africa together with early-stage venture capital firm, Flat6Labs, the result of its first official regional collaboration. Together the companies will support female-led and focused start-ups in the digital healthcare space, supporting them in the development of a Medium Viable Product (MVP). Selected start-ups will participate in a two-month intensive acceleration program featuring one-on-one coaching and mentoring with relevant leading sector experts, online training, and matchmaking with potential technical, investment and business partners.
Copyright © 2021 Organon group of companies. All rights reserved. In case you need any update, or you have an inquiry or need to report an adverse reaction, you can contact:
Tel.: +9714 5639700 Fax: +9714 5805629 Email: email@example.com
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows that will support investments in future growth opportunities in women's health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
View original content to download multimedia: https://www.prnewswire.com/news-releases/organon-announces-commitment-to-accelerating-advancements-in-womens-health-at-expo-2020-301409930.html